Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma

World Journal of Hepatology

Volumn 2, Issue 3, 2010, Pages 94-102

  Zhang, Yu Jing ^a  

^a Mailman School of Public Health and Cancer Center of Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960326845     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v2.i3.94     Document Type: Article

References (118)

1. Schafer DF. and Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-1257
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
4. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 2002; 36: 1046-1049
5. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002; 181-182: 43-47
6. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007; 26: 2166-2176
7. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36: 1214-1220
8. Wogan GN, Newberne PM. Dose-response characteristics of aflatoxin B1 carcinogenesis in the rat. Cancer Res 1967; 27: 2370-2376
9. IARC. Monographs on the evaluation of carcinogenic risk to humans. Lyon, France: IARC Publications, 1987
10. Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res 1992; 52: 2114s-2118s
11. Wogan GN. Aflatoxins and their relationship to hepatocellular carcinoma. In: Okuda K and Peters RL, editors. Hepatocellular Carcinoma. New York: John Wiley and Sons, 1976: 25-42
12. Newberne PM, Wogan GN. Sequential morphologic changes in aflatoxin B carcinogenesis in the rat. Cancer Res 1968; 28: 770-781
13. Swenson DH, Miller EC, and Miller JA. Aflatoxin B1-2,3- oxide: evidence for its formation in rat liver in vivo and by human liver microsomes in vitro. Biochem Biophys Res Commun 1974; 60: 1036-1043
14. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, and Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946
15. Croy RG, Essigmann JM, Reinhold VN, and Wogan GN. Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci USA 1978; 75: 1745-1749
16. Yu FL, Bender W, Hutchcroft A. Studies on the binding and transcriptional properties of aflatoxin B1-8,9-epoxide. Carcinogenesis 1994; 15: 1737-1741
17. Santella RM, Chen CJ, Zhang YJ, Yu MW, and Wang LY. Biological markers of aflatoxin B1 in hepatocellular cancer in Taiwan. In: Mendelsohn ML, Mohr LC and Peeters JP, editors. Biomarkers medical and workplace applications. Washington, DC: Joseph Henry Press, 1998: 355-364
18. Meneghini R, Schumacher RI. Aflatoxin B1, a selective inhibitor of DNA synthesis in mammalian cells. Chem Biol Interact 1977; 18: 267-276
19. Amstad P, Cerutti P. DNA binding of aflatoxin B1 by cooxygenation in mouse embryo fibroblasts C3H/10T1/2. Biochem Biophys Res Commun 1983; 112: 1034-1040
20. Chen CJ, Zhang YJ, Lu SN, Santella RM. Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. Hepatology 1992; 16: 1150-1155
21. Zhang YJ, Chen CJ, Lee CS, Haghighi B, Yang GY, Wang LW, Feitelson M, Santella R. Aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Carcinogenesis 1991; 12: 2247-2252
22. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Santella RM. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57: 3471-3477
23. Lin JK, Miller JA, Miller EC. 2,3-Dihydro-2-(guan-7-yl)-3- hydroxy-aflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res 1977; 37: 4430-4438
24. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428
25. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431
26. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3-10
27. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, Wu MH, Wu WP, Wang LW, Wang Q, Huang GT, Yang PM, Lee HS, and Santella RM. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67: 620-625
28. Wu HC, Wang Q, Wang LW, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM. Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis 2007; 28: 995-999
29. Wong N, Lai P, Pang E, Fung LF, Sheng Z, Wong V, Wang W, Hayashi Y, Perlman E, Yuna S, Lau JW, Johnson PJ. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res 2000; 6: 4000-4009
30. Aguilar F, Hussain P, and Cerutti P. Aflatoxin B1 induces the transversion of G- T in codon 249 of the p53 tumor suppressor gene in human hepatyocytes. Proc Natl Acad Sci USA 1993; 90: 8586-8590
31. Macé K, Aguilar F, Wang JS, Vautravers P, Gómez-Lechón M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 1997; 18: 1291-1297
32. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trépo C, Bréchot C, Hainaut P, Montesano R. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst 2000; 92: 148-153
33. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, Wu Y, Kensler TW, Vogelstein B, Groopman JD. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001; 61: 33-55
34. Kuang SY, Lekawanvijit S, Maneekarn N, Thongsawat S, Brodovicz K, Nelson K, Groopman JD. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev 2005; 14: 380-384
35. McMaho G, Davis EF, Huber LJ, Kim Y, and Wogan GN. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. Proc Natl Acad Sci USA 1990; 87: 1104-1108
36. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989; 80: 196-199
37. Ricordy R, Gensabella G, Cacci E, Augusti-Tocco G. Imp- airment of cell cycle progression by aflatoxin B1 in human cell lines. Mutagenesis 2002; 17: 241-249
38. Stettler PM, Sengstag C. Liver carcinogen aflatoxin B1 as an inducer of mitotic recombination in a human cell line. Mol Carcinog 2001; 31: 125-138
39. Kaplanski C, Chisari FV, Wild CP. Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Carcinogenesis 1997; 18: 633-639
40. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 2002; 17: 471-481
41. IARC. Vinyl chloride IARC Monograph on evolution of carcinogenic risk of chemicals to humans.Washington DC: US Govt, 1974
42. Guengerich FP. Roles of the vinyl chloride oxidation products 1-chlorooxirane and 2-chloroacetaldehyde in the in vitro formation of etheno adducts of nucleic acid bases [corrected]. Chem Res Toxicol 1992; 5: 2-5
43. Barbin A, Froment O, Boivin S, Marion MJ, Belpoggi F, Maltoni C, Montesano R. p53 gene mutation pattern in rat liver tumors induced by vinyl chloride. Cancer Res 1997; 57: 1695-1698
44. Tamburro CH, Makk L, Popper H. Early hepatic histologic alterations among chemical (vinyl monomer) workers. Hepatology 1984; 4: 413-418
45. Evans DM, Williams WJ, Kung IT. Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers. Histopathology 1983; 7: 377-388
46. Weihrauch M, Benick M, Lehner G, Wittekind M, Bader M, Wrbitzk R, Tannapfel A. High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health 2001; 74: 405-410
47. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in wokers exposed to vinyl chloride. Br J Cancer 2001; 84: 982-989
48. Weihrauch M, Lehnert G, Kockerling F, Wittekind C, and Tannapfel A. p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride. Cancer 2000; 88: 1030-1036
49. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42
50. Tu JT, Gao RN, Zhang DH, Gu BC. Hepatitis B virus and primary liver cancer on Chongming Island, People's Republic of China. Natl Cancer Inst Monogr 1985; 69: 213-215
51. Goodman MT, Moriwaki H, Vaeth M, Akiba S, Hayabuchi H, Mabuchi K. Prospective cohort study of risk factors for primary liver cancer in Hiroshima and Nagasaki, Japan. Epidemiology 1995; 6: 36-41
52. Phillips DH. Polycyclic aromatic hydrocarbons in the diet. Mutat Res 1999; 443: 139-147
53. IARC Polynuclear Aromatic Compounds, Part 1. Chemical Environmental nd Experimental Data. IARC Monographs on the Evaluation ofthe Carcinogenic Risk of Chemicals to Humans. International Agency for Research on Cancer, 1983: 1-453
54. Rodriguez LV, Dunsford HA, Steinberg M, Chaloupka KK, Zhu L, Safe S, Womack JE, Goldstein LS. Carcinogenicity of benzo[a]pyrene and manufactured gas plant residues in infant mice. Carcinogenesis 1997; 18: 127-135
55. Baumann PC, Harshbarger JC. Decline in liver neoplasms in wild brown bullhead catfish after coking plant closes and environmental PAHs plummet. Environ Health Perspect 1995; 103: 168-170
56. Chen SY, Wang LY, Lunn RM, Tsai WY, Lee PH, Lee CS, Ahsan H, Zhang YJ, Chen CJ, Santella RM. Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer 2002; 99: 14-21
57. Zhang YJ, Rossner P Jr, Chen Y, Agrawal M, Wang Q, Wang L, Ahsan H, Yu MW, Lee PH, Santella RM. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer 2006; 119: 985-991
58. Bartsch H, Malaveille C, Friesen M, Kadlubar FF, and Vineis P. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 1993; 29: 1199-1207
59. Butler MA, Iwasaki M, Guengerich FP, and Kadlubar, FF. Human cytochrome P-450A (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-7700
60. Talaska G, Dooley KL, Kadlubar FF. Detection and characterization of carcinogen-DNA adducts in exfoliated urothelial cells from 4-aminobiphenyl-treated dogs by 32P-postlabelling and subsequent thin-layer and high-pressure liquid chromatography. Carcinogenesis 1990; 11: 639-646
61. Kadlubar FF. DNA adducts of carcinogenic aromatic amines. In: Hemminki KDASDE, editors. DNA adducts identification and biological significance (IARC Scientific Publication No.125). New York: Oxford University Press, 1994: 199-215
62. Poirier MC, Fullerton NF, Smith BA, Beland FA. DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. Carcinogenesis 1995; 16: 2917-2921
63. Wang LY, Chen CJ, Zhang YJ, Tsai WY, Lee PH, Feitelson MA, Lee CS, Santella RM. 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am J Epidemiol 1998; 147: 315-323
64. Curigliano G, Zhang YJ, Wang LY, Flamini G, Alcini A, Ratto C, Giustacchini M, Alcini E, Cittadini A, Santella RM. Immunohistochemical quantitation of 4-aminobiphenyl- DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis 1996; 17: 911-916
65. IARC. IARC Monographys on evaluation of carcinogenic risk to humans. In Some Drinking Water Disinfectants and Contaminants, including Arsenic. International Agency for Research on Cancer. IARC Monogr Eval Carcinog Risks Hum 2004; 84: 296-477
66. Chen CJ, Lin L. Carcinigenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In: Nriagu O, editor. Arsenic in the Environment. New York: John Wiley & Sons Inc, 1994: 109-131
67. Waalkes MP, Liu J, Diwan BA. Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol 2007; 222: 271-280
68. Liu J, Waalkes MP. Liver is a target of arsenic carcinogenesis. Toxicol Sci 2008; 105: 24-32
69. Waalkes MP, Ward JM, Diwan BA. Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. Carcinogenesis 2004; 25: 133-141
70. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001; 61: 5389-5395
71. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S294-S308
72. McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, and Barve, S. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol 2002; 27: 185-192
73. Marrogi AJ, Khan MA, van Gijssel HE, Welsh JA, Rahim H, Demetris AJ, Kowdley KV, Hussain SP, Nair J, Bartsch H, Okby N, Poirier MC, Ishak KG, Harris CC. Oxidative stress and p53 mutations in the carcinogenesis of iron overloadassociated hepatocellular carcinoma. J Natl Cancer Inst 2001; 93: 1652-1655
74. Kurz DJ, Decary S, Hong Y, Trivier E, Akhmedov A, Erusalimsky JD. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004; 117: 2417-2426
75. Gonzalez FJ, Lee YH. Constitutive expression of hepatic cytochrome P450 genes. FASEB J 1996; 10: 1112-1117
76. Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, and Langouet S. Activation and detoxification of aflatoxin B1. Mutat Res 1998; 402: 121-128
77. Iyer R, Voehler M, and Harris TM. Adenine adduct of aflatoxin B1 epoxide. J Am Chem Soc 1994; 116: 8863-8869
78. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, Juillerat M, Lipsky MM, Trump BF. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci USA 1993; 90: 5123-5127
79. Zhang YJ, Chen SY, Tsai WY, Ahsan H, Lunn R, Wang LY, Chen CJ, and Santella RM. Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1- and 4-aminobiphenyl- DNA adducts. Biomarkers 2000
80. Harris CC. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1989; 10: 1563-1566
81. Langouët S, Coles B, Morel F, Becquemont L, Beaune P, Guengerich FP, Ketterer B, Guillouzo A. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res 1995; 55: 5574-5579
82. Raney KD, Meyer DJ, Ketterer B, Harris TM, and Guengerich FP. Glutathione conjugation of aflatoxin B1 exo- and endoepoxide by rat and human glutathione S-transferases. Chem Res Toxicol 1992; 5: 470-478
83. Johnson WW, Ueng YF, Widersten M, Mannervik B, Hayes JD, Sherratt PJ, Ketterer B, and Guengerich FP. Conjugation of highly reactive aflatoxin B1 exo-8,9-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. Biochemistry 1997; 36: 3056-3060
84. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper M., Zhou T, Wild CP, Xia XL, Baffoe-Bonnie,A, Ofori-Adjei D, Chen GC, London WT, Shen FJ, and Buetow KH. Susceptibility to hepatocellular carcinoma is associated with gentic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995; 92: 2384-2387
85. Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, Hirvonen A, Bell DA, and Santella RM. Chronic hepatitis B carriers with null genotypes of gluthione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 1996; 59: 128-134
86. Pemble S, Schiroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, and Taylor JB. Human glutathione S-transferase theta (GSTT1) cDNA cloning and the characterization of a genetic polymorphism. Biochem 1994; 300: 271-276
87. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, and Malkowicz SB. Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 283-287
88. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, Whittle H, Kirk GD, and Hall AJ. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000; 86: 1-7
89. Sun CA, Wang LY, Chen CJ, Lu SN, You SL, Wang LW, Wang Q, Wu DM and Santella RM. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001; 22: 1289-1294
90. Guengerich FP, Kim DH, and Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168-179
91. Grollman A, Shibutani S. Mutagenic specificity of chemical carcinogens as determined by studies of single DNA adducts. In: IARC, editor. DNA Adducts: Identification and Biological Significance. Lyon: Scientific Publ, 1994: 385-397
92. Agency for toxic substances and disease registry toxilogical profile for vinyl chloride. In US Department of Health and Human Services, editor. Atlanta, 1997
93. Vineis P. Individual susceptibility to carcinogens. Oncogene 2004; 23: 6477-6483
94. Ketterer B. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat Res 1988; 202: 343-361
95. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000; 464: 65-76
96. Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, and Guengerich FP. Characterization of human lung microsomal cytochrome P450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharm 1992; 41: 856-864
97. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, and Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239-249
98. Yu MW, Chiu YH, Yang SY, Santella RM, Chern HD, Liaw YF, and Chen CJ. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Brit J Cancer 1999; 80: 598-603
99. Li R, Shugart YY, Zhou W, An Y, Yang Y, Zhou Y, Zhang B, Lu D, Wang H, Qian J, and Jin L. Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population. Eur J Cancer 2009; 45: 1239-1247
100. Chen X, Wang H, Xie W, Liang R, Wei Z, Zhi L, Zhang X, Hao B, Zhong S, Zhou G, Zhang L, Gao X, Zhu Y, and He F. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet Genomics 2006; 16: 219-227
101. Lam KC, Yu MC, Leung JWC and Henderson BE. Hepatitis B virus and cigarette smoking: risk factors for hepatocellural carcinoma in Hong Kong. Cancer Res 1982; 42: 5246-5248
102. Mannervik B, Danielson UH. Glutathione transferases--structure and catalytic activity. CRC Crit RevBiochem 1988; 23: 283-337
103. Daniel V. Glutathione S-transferases: gene structure and regulation of expression. Crit Rev Biochem Mol Biol 1993; 28: 173-207
104. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600
105. Zhou T, Evans AA, London WT, Xia X, Zou H, Shen F, and Clapper ML. Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis. Cancer Res 1997; 57: 2749-2753
106. Yu MW, Chiu YH, Chiang YC, Chen CH, Lee TH, Santella RM., Chern HD, Liaw YF, and Chen CJ. Plasma carotenoids, glutatione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Am J Epidemiol 1999; 149: 621-629
107. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, and Katoh T. Genetic polymorphisms of tobacco-and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol 2003; 129: 355-360
108. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, and Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993: 14: 1633-1638
109. Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, and Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996; 6: 501-512
110. Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM, Liaw YF, Chen PJ and Chen CJ. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut 2000; 47: 703-709
111. Farker K, Schotte U, Scheele J, and Hoffmann A. Impact of N-acetyltransferase polymorphism (NAT2) in hepatocellular carcinoma (HCC)-an investigation in a department of surgical medicine. Exp Toxicol Pathol 2003; 54: 387-391
112. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw Y. F, and Chen CJ. Cytochrome P-450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroent 1995; 109: 1266-1273
113. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 2000; 112-113: 209-217
114. Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA, Walsh B, Avram MD, Kopplin MJ, Cebrian ME, Silbergeld EK, and Aposhian HV. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 2003; 16: 1507-1513
115. Marcos R, Martinez V, Hernandez A, Creus A, Sekaran C, Tokunaga H, and Quinteros D. Metabolic profile in workers occupationally exposed to arsenic: role of GST polymorphisms. J Occup Environ Med 2006 48: 334-341
116. Tanaka E, Terada M, and Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000; 25: 165-175
117. Morgan K, French SW, and Morgan TR. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 2002; 36: 122-134
118. Ho JC, Cheung ST, Leung KL, Ng IO, and Fan ST. Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma. Int J Cancer 2004; 111: 494-500